Biologics are helpful for the treatment of nasal polyps, whether or not concomitant asthma is present. The choice relies on patient and provider preference and insurance coverage, as elucidated from a study issued in "Journal of Pharmacy Technology". Investigators sought to examine published research on biological nasal polyp therapy. Utilizing relevant search words like biologics, reslizumab, omalizumab, mepolizumab, or dupilumab AND nasal polyposis, nasal polyps, or chronic rhinosinusitis with nasal polyposis (CRSwNP), PubMed was searched.

English-language, published meta-analyses, randomized trials, and post hoc analyses investigating biologics for nasal polyposis, with or without concomitant asthma, were required for inclusion. Through the use of primary and tertiary literature references, further assessment was done. A total of 19 studies assessed safety and effectiveness of biologics for nasal polyposis, including 9 post hoc analyses, 2 meta-analyses, and 8 trials.

Reslizumab, Omalizumab, Mepolizumab, Dupilumab, and Benralizumab were among the agents investigated. Similar inclusion (recurrent and refractory CRSwNP) and exclusion criteria were used across studies. Apart from the biologic or placebo, all the investigations used a corticosteroid (intranasal fluticasone or mometasone). Alteration in endoscopic nasal polyp score was the key outcome ascertained.

Reslizumab, Omalizumab, Benralizumab, Mepolizumab, and Dupilumab treatment improved endoscopic, clinical, and/or radiographic outcomes in persons suffering from CRSwNP who had or did not have concomitant asthma in all studies, post hoc analyses, and meta-analyses. Most data has been reported for Dupilumab. The only biologics that are currently Food and Drug Administration (FDA)-approved for CRSwNP are Dupilumab, Mepolizumab, and Omalizumab. Thus, biologics are valuable for CRSwNP management.